REPLIGEN CORP Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
REPLIGEN CORP (RGEN) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $19.20 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-07-29
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $19.20M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $28.86M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $9.86M.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $19.90M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $19.20M 10-Q · filed 2026-07-29 |
| 2026-03-31 | $28.86M 10-Q · filed 2026-05-06 |
| 2025-09-30 | $9.86M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $19.90M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $28.27M 10-Q · filed 2025-04-29 |
| 2024-09-30 | $8.62M 10-Q · filed 2024-11-18 |
| 2022-09-30 | $7.32M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $13.18M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $19.85M 10-Q · filed 2022-04-27 |
| 2021-09-30 | $7.00M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $10.38M 10-Q · filed 2021-07-27 |
| 2021-03-31 | $15.56M 10-Q · filed 2021-05-04 |
| 2020-09-30 | $3.96M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $7.40M 10-Q · filed 2020-07-30 |
| 2020-03-31 | $11.35M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $15.29M 10-K · filed 2020-02-26 |
| 2019-09-30 | $3.92M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $8.31M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $7.85M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $134.74M 10-K · filed 2019-03-01 |
| 2018-09-30 | $2.64M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $5.28M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $7.98M 10-Q · filed 2018-05-08 |
| 2017-09-30 | $2.63M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $1.71M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $2.27M 10-Q · filed 2017-05-04 |
| 2016-09-30 | $553.00K 10-Q · filed 2016-11-03 |
| 2016-06-30 | $1.12M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $1.28M 10-Q · filed 2016-05-05 |
| 2015-09-30 | $443.00K 10-Q · filed 2015-11-05 |
| 2015-06-30 | $845.00K 10-Q · filed 2015-08-06 |
| 2015-03-31 | $1.25M 10-Q · filed 2015-05-08 |
| 2014-09-30 | $1.17M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $1.76M 10-Q · filed 2014-08-11 |
| 2014-03-31 | $1.00M 10-Q · filed 2014-05-09 |
| 2013-09-30 | $1.00M 10-Q · filed 2013-11-08 |
| 2013-06-30 | $1.00M 10-Q · filed 2013-08-07 |
| 2013-03-31 | $1.00M 10-Q · filed 2013-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |